Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Monthly Archives: August 2015

Congress Explores Patent Reform; Tech Companies and Life Sciences Industries Differ on Approach

Patent Reform capitolWashington, DC, August 26, 2015 ― Brian Fung reports in The Washington Post that, for much of this year, Congress has been grappling with how to update the nation’s patent laws.

On one side of the battle are tech companies and retail businesses whose owners argue that they’re getting killed by abusive patent lawsuits.

On the other side are research universities and life-sciences companies that view patents, and defending patents against infringement, as a key part of their business model. Continue reading

U.S. Government’s Vaccine-Injury Program Payouts Rise; Compensates When Vaccinations Improperly Injected

Washington, DC, August 25, 2015 ― Ianthe Jeanne Dugan today reports in The Wall Street Journal that a government program that pays people hurt by vaccinations recently doled out more than $1 million to Latasha George, a Louisiana nurse.

In addition, Katherine Brooks, an Indiana emergency-room doctor, received $92,500. Roberta Livolsi, a retired Pennsylvania housekeeper, got $75,000.

Why?  Each of these three patients was deemed victims of the flu shot — but their injuries had nothing to do with what was in the syringe.  Rather, they were among dozens that have been diagnosed with “Sirva,” or shoulder injury related to vaccine administration.  They were hurt by how the shot was given, not the contents of the vaccine. Continue reading

World Alzheimer Report: Nearly 47 Million Globally Living with Dementia; Associated Costs Forecast to Reach $1 Trillion by 2018

Alzheimer's puzzleLondon, England, August 25, 2015 ― An Associated Press story published in The Washington Post reports that health researchers say there are now 46.8 million people living with dementia globally, up from 35 million in 2009.

There is currently no known cure for dementia.

The researchers warned that without a medical breakthrough, numbers will likely double every 20 years.

In a report issued on Tuesday, researchers from Alzheimer’s Disease International say about 58 percent of all people with dementia live in developing countries and that by 2050, nearly half of all those with the disease will live in Asia.   Continue reading

Event: Rutgers Cancer Institute of NJ to Host Symposium on Cancer-Treatment ‘Pipeline’ October 19

Rutgers CINJ Logo

New Brunswick, NJ, August 24, 2015Rutgers Cancer Institute of New Jersey will host a “what’s-in-the-pipeline” symposium with industry from 4:00 to 6:00 p.m. in Auditorium A and B at 195 Little Albany Street in New Brunswick.

Co-sponsored by the HealthCare Institute of New Jersey (HINJ), the forum is designed to foster collaboration and networking between Rutgers faculty and strategic industry partners.

Attendees will have an update on drugs in the development pipeline at Merck & Co. and industry executives will hear about basic clinical investigations at Rutgers.

Registration is not required. Continue reading

Second Cancers Are on Rise; 1 in 5 U.S. Cases Is a Repeat

Washington, DC, August 24, 2015 ― Marilynn Marchione reports in an Associated Press story published today in The Washington Post that second cancers are on the rise.  Nearly one in five new cases in the US now involves someone who has had the disease before.

When doctors talk about second cancers, they mean a different tissue type or a different site, not a recurrence or spread of the original tumor.

About 19 percent of cancers in the United States now are second-or-more cases, a recent study found.  In the 1970s, it was only 9 percent.  Over that period, the number of first cancers rose 70 percent while the number of second cancers rose 300 percent. Continue reading

NIH Study Explores Pain in America; 40 Million Experience Severe Pain

Pain in America NIHBethesda, MD, August 24, 2015 ― Kaiser Health News today reports that, in one of the largest population studies on pain to date, researchers with the National Institutes of Health estimate that nearly 40 million Americans experience severe pain and more than 25 million have pain every day.

Those with severe pain were more likely to have worse health status, use more health care and suffer from more disability than those with less severe pain. Continue reading

Insurer, New Jersey Medical Associations Seek Solution to Surprise Out-of-Network Medical Bills

Woodland Park, NJ, August 24, 2015 ― Lindy Washburn reports in The Record that New Jersey’s largest health insurance company and organizations representing doctors and hospitals have held private discussions over the summer about legislation to protect consumers from surprise medical bills.

They haven’t hammered out a compromise yet over the toughest issue — how to determine how much to pay a provider who isn’t part of an insurance network — but one participant expressed optimism. Continue reading

NIH Joins Public-Private Partnership to Fund Research on Autism Biomarkers

Bethesda, MD, August 23, 2015 ― In July, the National Institutes of Health (NIH) announced that government, nonprofit and other private partners will fund a multi-year project to develop and improve clinical research tools for studying autism spectrum disorder (ASD).

The project will receive a total of $28 million over the next four years to test and refine clinical measures of social impairment in ASD in order to better evaluate potential behavioral and drug therapies.

It is supported by the National Institutes of Health (NIH), the Foundation for the NIH (FNIH), the Simons Foundation Autism Research Initiative (SFARI), and others.  Continue reading

PhRMA Publishes Report on Alzheimer’s Research; ‘Setbacks’ Critical for Breakthroughs of Tomorrow

PhRMA jpgWashington, DC, August 22, 2015 ― The Pharmaceutical Research and Manufacturers of America (PhRMA) in July released a new report, “Researching Alzheimer’s Medicines: Setbacks and Stepping Stones,” that found 123 potential medicines for Alzheimer’s disease were halted in clinical trials between 1998 and 2014, while four medicines were approved during the same timeframe.

While this 30-to-1 ratio of setbacks to successes demonstrates the challenge and complexity of Alzheimer’s research, it is important to recognize the role of these so-called “failures” in advancing knowledge and laying the foundation for future advances.

The report features a foreword by Robert Egge, executive director, Alzheimer’s Impact Movement (AIM, a sister organization of the Alzheimer’s Association), highlighting the collaborative role of biopharmaceutical companies in developing new treatments for Alzheimer’s disease. Continue reading

Survey: Drug Costs Dislodge Obamacare as GOP Voters’ Top Health Care Concern

Washington, DC, August 22, 2015 Politico reports that, in April, the nonpartisan Kaiser Family Foundation was surprised by a poll showing more Republicans view drug prices — and not Obamacare’s repeal — as the No. 1 health care priority.

So it looked further.  The results, released Thursday, show that nearly three-quarters of Americans think drug prices are unreasonably high — and most blame that on drug companies’ drive for profits.  Continue reading